Chinese vaccine producer Sinopharm’s inactivated COVID-19 vaccine does not increase the risk of thrombosis or thrombocytopenia in recipients and the latest real world data form Argentina shows that the vaccine has an 84 percent death-protection efficacy among people aged 60 and above, according to a statement from China National Biotec Group (CNBG), a subsidiary of Sinopharm.